HSD-016 (HSD016) is a novel 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor (IC50 = 11, 1 and 8 nM for human, mouse and rat 11β-HSD1, respectively) with the potential to be used for type 2 diabetes.
Physicochemical Properties
| Molecular Formula | C21H21F7N2O3S |
| Molecular Weight | 514.46 |
| Exact Mass | 514.116 |
| Elemental Analysis | C, 49.03; H, 4.11; F, 25.85; N, 5.45; O, 9.33; S, 6.23 |
| CAS # | 946396-92-5 |
| PubChem CID | 16721125 |
| Appearance | White to off-white solid powder |
| LogP | 5.597 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 12 |
| Rotatable Bond Count | 4 |
| Heavy Atom Count | 34 |
| Complexity | 817 |
| Defined Atom Stereocenter Count | 2 |
| SMILES | S(C1C=CC=C([C@](C)(C(F)(F)F)O)C=1)(N1CCN(C2C=CC(=CC=2C(F)(F)F)F)C[C@H]1C)(=O)=O |
| InChi Key | ZWASRJHIEFYJGL-BFUOFWGJSA-N |
| InChi Code | InChI=1S/C21H21F7N2O3S/c1-13-12-29(18-7-6-15(22)11-17(18)20(23,24)25)8-9-30(13)34(32,33)16-5-3-4-14(10-16)19(2,31)21(26,27)28/h3-7,10-11,13,31H,8-9,12H2,1-2H3/t13-,19-/m1/s1 |
| Chemical Name | (R)-1,1,1-trifluoro-2-(3-(((R)-4-(4-fluoro-2-(trifluoromethyl)phenyl)-2-methylpiperazin-1-yl)sulfonyl)phenyl)propan-2-ol |
| Synonyms | HSD-016 HSD-16HSD 16HSD 016 HSD016 HSD16 |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| References |
[1]. Synthesis of potent and orally efficacious 11β-hydroxysteroid dehydrogenase type 1 inhibitor HSD-016. J Org Chem. 2011 Sep 2;76(17):7048-55. |
| Additional Infomation | Hsd 016 is under investigation in clinical trial NCT00838461 (Study Evaluating the Safety, Pharmacokinetics (PK), and Pharmacodynamices (PD) of HSD-016). |
Solubility Data
| Solubility (In Vitro) | DMSO : ~100 mg/mL (~194.38 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.5 mg/mL (4.86 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.86 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9438 mL | 9.7189 mL | 19.4379 mL | |
| 5 mM | 0.3888 mL | 1.9438 mL | 3.8876 mL | |
| 10 mM | 0.1944 mL | 0.9719 mL | 1.9438 mL |